<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Emirati Study: Clinical Research — Insomnia Pharmacology & Treatment Landscape in the UAE (2026) </title>

    <style>
        body {
            <!-- Loading Overlay -->
<div id="loading-overlay">
    <div id="loading-box">
        <div id="loading-text">0%</div>
    </div>
</div>

<!-- Top Navigation (for loading animation) -->
<nav style="text-align:center; padding:10px;">
    <a href="index.html" style="color:#00ff88; text-decoration:none; font-weight:bold;">
        ← Back to Home
    </a>
</nav>

            margin: 0;
            padding: 0;
            background-color: #000;
            color: #fff;
            font-family: sans-serif;
        }

        /* Sidebar */
        .sidebar {
            position: fixed;
            top: 0;
            left: 0;
            width: 260px;
            height: 100%;
            background-color: #0a0a0a;
            border-right: 2px solid #00ff88;
            padding: 20px;
            box-shadow: 0 0 20px #00ff88;
            overflow-y: auto;
        }

        .sidebar h2 {
            color: #00ff88;
            font-size: 22px;
            margin-bottom: 20px;
            text-align: center;
        }

        .sidebar a {
            display: block;
            color: #c8ffc8;
            text-decoration: none;
            margin: 10px 0;
            font-size: 15px;
            transition: 0.2s;
        }

        .sidebar a:hover {
            color: #00ff88;
            margin-left: 6px;
        }

        /* Main Content */
        .content {
            margin-left: 280px;
            padding: 30px;
        }

        h1 {
            font-size: clamp(24px, 6vw, 36px);
            color: #00ff88;
            text-align: center;
        }

        h2 {
            font-size: clamp(20px, 5vw, 30px);
            color: #00ff88;
            margin-top: 10px;
            margin-bottom: 15px;
        }

        h3 {
            font-size: clamp(18px, 4.5vw, 24px);
            color: #00ff88;
            margin-top: 10px;
            margin-bottom: 10px;
        }

        p, li {
            font-size: clamp(14px, 4vw, 18px);
            line-height: 1.8;
            color: #e0ffe0;
        }

        ul {
            padding-left: 20px;
        }

        /* Neon Boxes */
        .box {
            background-color: #111;
            border: 1px solid #00ff88;
            box-shadow: 0 0 15px #00ff88;
            border-radius: 10px;
            padding: 20px;
            margin: 25px 0;
        }

        .meta {
            text-align: center;
            color: #c8ffc8;
            margin-bottom: 10px;
        }

        /* Tables */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            background-color: #111;
            box-shadow: 0 0 15px #00ff88;
        }

        th, td {
            border: 1px solid #00ff88;
            padding: 10px;
            text-align: left;
            color: #e0ffe0;
            vertical-align: top;
        }

        th {
            background-color: #00ff88;
            color: #000;
        }

        /* Potency Badges */
        .badge {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 999px;
            font-size: 11px;
            font-weight: bold;
            letter-spacing: 0.5px;
            color: #000;
            margin-right: 6px;
            box-shadow: 0 0 8px rgba(0,0,0,0.8);
        }

        .badge-light {
            background-color: #3aa0ff;
            box-shadow: 0 0 10px #3aa0ff;
        }

        .badge-moderate {
            background-color: #ffd93a;
            box-shadow: 0 0 10px #ffd93a;
        }

        .badge-potent {
            background-color: #ff9b3a;
            box-shadow: 0 0 10px #ff9b3a;
        }

        .badge-extreme {
            background-color: #ff3a3a;
            box-shadow: 0 0 12px #ff3a3a;
        }

        .potency-text {
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 0.6px;
            color: #c8ffc8;
        }

        /* Mobile Responsive */
        @media (max-width: 900px) {
            .sidebar {
                position: relative;
                width: 100%;
                height: auto;
                border-right: none;
                border-bottom: 2px solid #00ff88;
            }

            .content {
                margin-left: 0;
                padding: 20px;
            }
        }
    </style>
</head>

<body>

<!-- Sidebar Navigation -->
<div class="sidebar">
    <h2>Insomnia Study</h2>
    <a href="#abstract">Abstract</a>
    <a href="#background">Background</a>
    <a href="#mechanisms">Mechanisms of Sleep</a>
    <a href="#classes">Drug Classes</a>
    <a href="#potency">Potency Framework</a>
    <a href="#uae-table">UAE Drug Availability</a>
    <a href="#novel">Novel & Emerging Treatments</a>
    <a href="#conclusion">Conclusion</a>
    <a href="#references">References</a>
    <hr style="border-color:#00ff88; margin:15px 0;"> <a href="https://khalidalmansoori.com/index.html" class="sidebar-home"> ← Back to Home </a>
</div>

<!-- Main Content -->
<div class="content">

    <h1>Emirati Study: Clinical Research — Insomnia Pharmacology & Treatment Landscape in the UAE (2026)</h1>
    <div class="meta">
        <strong>Principal Investigator:</strong> Khalid Almansoori<br>
        <strong>Location:</strong> United Arab Emirates<br>
        <strong>Type:</strong> Educational Clinical‑Pharmacology Review (Non‑Interventional)
    </div>

    <!-- Abstract -->
    <div class="box" id="abstract">
        <h2>Abstract</h2>
        <p>
            This educational clinical‑pharmacology review summarizes the mechanisms of sleep regulation and the
            pharmacological agents currently used for insomnia within the United Arab Emirates. It focuses on
            receptor‑level mechanisms, relative sedative potency, and practical availability across government and
            private sectors, including community pharmacies. Drug classes covered include benzodiazepine receptor
            agonists (Z‑drugs and benzodiazepines), sedating antidepressants, antihistamines, gabapentinoids,
            orexin receptor antagonists, and other adjunctive agents. The goal is to provide clinicians in the UAE
            with a structured, mechanism‑based overview of insomnia treatments and their local availability, without
            making therapeutic recommendations or replacing clinical judgment.
        </p>
    </div>

    <!-- Background -->
    <div class="box" id="background">
        <h2>Background</h2>
        <p>
            Insomnia is highly prevalent and frequently comorbid with psychiatric, neurological, and medical
            conditions. Pharmacological treatment remains common in clinical practice, despite the central role of
            non‑pharmacological approaches such as cognitive‑behavioural therapy for insomnia (CBT‑I). In the UAE,
            clinicians navigate a mixed landscape of government‑restricted medications, private‑sector availability,
            and over‑the‑counter options. Understanding the mechanisms of action and relative sedative potency of
            available agents is essential for rational, individualized prescribing within local regulatory and
            formulary constraints.
        </p>
    </div>

    <!-- Mechanisms of Sleep -->
    <div class="box" id="mechanisms">
        <h2>Mechanisms of Sleep Regulation</h2>
        <p>
            Sleep–wake regulation is governed by interacting neurotransmitter systems and circadian processes:
        </p>
        <ul>
            <li><strong>GABAergic inhibition:</strong> GABA neurons in the ventrolateral preoptic nucleus (VLPO) inhibit
                wake‑promoting nuclei, reducing cortical arousal.</li>
            <li><strong>Orexin (hypocretin):</strong> Orexin neurons in the lateral hypothalamus stabilize wakefulness by
                exciting monoaminergic and cholinergic arousal systems.</li>
            <li><strong>Melatonin and circadian timing:</strong> Melatonin acting at MT<sub>1</sub>/MT<sub>2</sub> receptors in the
                suprachiasmatic nucleus modulates circadian phase and sleep propensity.</li>
            <li><strong>Adenosine:</strong> Accumulates during wakefulness and promotes sleep by inhibiting wake‑promoting
                neurons.</li>
            <li><strong>Histamine:</strong> Histaminergic neurons in the tuberomammillary nucleus promote wakefulness via
                H<sub>1</sub> receptors; H<sub>1</sub> antagonism is sedating.</li>
        </ul>
        <p>
            Most hypnotic drugs act by either enhancing GABAergic inhibition, blocking wake‑promoting systems
            (histamine, orexin), or modulating circadian signalling.
        </p>
    </div>

    <!-- Drug Classes -->
    <div class="box" id="classes">
        <h2>Pharmacological Classes Used for Insomnia</h2>

        <h3>Z‑Drugs (Non‑benzodiazepine GABA<sub>A</sub> Agonists)</h3>
        <p>
            Zopiclone, eszopiclone, zolpidem, and zaleplon are positive allosteric modulators at the benzodiazepine
            site of GABA<sub>A</sub> receptors, with relative selectivity for α<sub>1</sub>‑containing subtypes. They enhance
            GABA‑mediated chloride influx, hyperpolarizing neurons and reducing arousal. They primarily target sleep
            onset (short‑acting agents) and/or sleep maintenance (longer‑acting or extended‑release formulations.
        </p>

        <h3>Benzodiazepines</h3>
        <p>
            Benzodiazepines (e.g., lorazepam, clonazepam, diazepam, bromazepam) are non‑selective positive allosteric
            modulators at GABA<sub>A</sub> receptors, enhancing GABA’s inhibitory effect across multiple α subunits. They
            provide anxiolytic, sedative, muscle‑relaxant, and anticonvulsant effects, with varying half‑lives and
            accumulation profiles. In the UAE, many are restricted to government hospitals and are not primarily
            positioned as first‑line hypnotics.
        </p>

        <h3>Orexin Receptor Antagonists</h3>
        <p>
            Dual orexin receptor antagonists (DORAs) such as lemborexant block OX<sub>1</sub>R and OX<sub>2</sub>R, reducing
            wake drive rather than amplifying GABAergic inhibition. This produces a more physiologic sleep profile,
            particularly for sleep maintenance, with less direct motor impairment compared to classic GABAergic
            sedatives.
        </p>

        <h3>Sedating Antidepressants</h3>
        <p>
            Agents such as amitriptyline, trazodone, and mirtazapine exert sedative effects primarily through
            H<sub>1</sub> histamine receptor antagonism and 5‑HT<sub>2</sub> receptor blockade, with additional noradrenergic and
            serotonergic actions. They are often used off‑label for insomnia in patients with comorbid mood or anxiety
            disorders.
        </p>

        <h3>Gabapentinoids and Other Off‑Label Agents</h3>
        <p>
            Gabapentin and pregabalin bind to the α<sub>2</sub>δ subunit of voltage‑gated calcium channels, reducing
            excitatory neurotransmitter release. They may improve sleep in patients with neuropathic pain or anxiety.
            Phenobarbital, a barbiturate, is rarely used due to safety and dependence concerns.
        </p>

        <h3>Antihistamines</h3>
        <p>
            First‑generation antihistamines (doxylamine, diphenhydramine, promethazine) block central H<sub>1</sub>
            receptors, reducing histamine‑mediated wakefulness. They are accessible but associated with anticholinergic
            effects, tolerance, and next‑day sedation, particularly in older adults.
        </p>
    </div>

    <!-- Potency Framework -->
    <div class="box" id="potency">
        <h2>Potency Framework (Educational Classification)</h2>
        <p>
            The following potency categories are <strong>educational</strong> and reflect relative sedative strength and
            CNS depressant profile, not prescribing recommendations:
        </p>
        <ul>
            <li><span class="badge badge-light">LIGHT</span>
                <span class="potency-text">Mild sedative effect; typically antihistamines or weak benzodiazepines.</span>
            </li>
            <li><span class="badge badge-moderate">MODERATE</span>
                <span class="potency-text">Clear sedative effect; often antidepressants, gabapentinoids, or low‑dose Z‑drugs.</span>
            </li>
            <li><span class="badge badge-potent">POTENT</span>
                <span class="potency-text">Strong hypnotic effect; typical of standard Z‑drug doses and many benzodiazepines.</span>
            </li>
            <li><span class="badge badge-extreme">EXTREMELY POTENT</span>
                <span class="potency-text">Very strong CNS depression; includes barbiturates, anesthetic benzodiazepines, and some DORAs.</span>
            </li>
        </ul>
        <p>
            This framework is intended to help clinicians conceptually position agents relative to one another; it does
            not replace dose‑specific, patient‑specific clinical judgment.
        </p>
    </div>

    <!-- UAE Drug Availability Table -->
    <div class="box" id="uae-table">
        <h2>UAE Insomnia‑Related Drug Availability (2026)</h2>
        <p>
            The table below summarizes selected agents relevant to insomnia in the UAE, with their class, potency
            category, and typical availability. Information is approximate and may change; clinicians should verify
            current formulary and regulatory status.
        </p>

        <h3>Z‑Drugs (Non‑benzodiazepine Hypnotics)</h3>
        <table>
            <tr>
                <th>Drug</th>
                <th>Class</th>
                <th>Potency</th>
                <th>Availability (UAE)</th>
                <th>Notes</th>
            </tr>
            <tr>
                <td>Zopiclone 7.5 mg</td>
                <td>Z‑drug (GABA<sub>A</sub> modulator)</td>
                <td>
                    <span class="badge badge-potent">POTENT</span>
                    <span class="potency-text">Hypnotic</span>
                </td>
                <td>Life Pharmacies (private)</td>
                <td>Commonly used for sleep onset and maintenance.</td>
            </tr>
            <tr>
                <td>Eszopiclone 1 mg</td>
                <td>Z‑drug</td>
                <td>
                    <span class="badge badge-moderate">MODERATE</span>
                    <span class="potency-text">Onset‑focused</span>
                </td>
                <td>Life Pharmacies (private)</td>
                <td>Lower dose; primarily sleep onset.</td>
            </tr>
            <tr>
                <td>Eszopiclone 3 mg</td>
                <td>Z‑drug</td>
                <td>
                    <span class="badge badge-potent">POTENT</span>
                    <span class="potency-text">Onset + maintenance</span>
                </td>
                <td>Life Pharmacies (private)</td>
                <td>Stronger hypnotic effect; longer duration.</td>
            </tr>
            <tr>
                <td>Zolpidem 10 mg</td>
                <td>Z‑drug</td>
                <td>
                    <span class="badge badge-potent">POTENT</span>
                    <span class="potency-text">Onset</span>
                </td>
                <td>Life Pharmacies (shortage reported)</td>
                <td>Primarily sleep onset; availability may fluctuate.</td>
            </tr>
            <tr>
                <td>Zolpidem 12.5 mg XR</td>
                <td>Z‑drug (extended‑release)</td>
                <td>
                    <span class="badge badge-potent">POTENT</span>
                    <span class="potency-text">Maintenance</span>
                </td>
                <td>Life Pharmacies (shortage reported)</td>
                <td>Designed for sleep maintenance; extended release.</td>
            </tr>
            <tr>
                <td>Zaleplon 5–10 mg</td>
                <td>Z‑drug (ultra‑short acting)</td>
                <td>
                    <span class="badge badge-moderate">MODERATE</span>
                    <span class="potency-text">Onset</span>
                </td>
                <td>Private sector (where stocked)</td>
                <td>Very short half‑life; minimal effect on maintenance.</td>
            </tr>
        </table>

        <h3>Benzodiazepines (Primarily Government Sector)</h3>
        <table>
            <tr>
                <th>Drug</th>
                <th>Class</th>
                <th>Potency</th>
                <th>Availability (UAE)</th>
                <th>Notes</th>
            </tr>
            <tr>
                <td>Lorazepam</td>
                <td>Benzodiazepine</td>
                <td>
                    <span class="badge badge-potent">POTENT</span>
                    <span class="potency-text">Sedative‑anxiolytic</span>
                </td>
                <td>Government hospitals</td>
                <td>Used mainly for anxiety and acute sedation.</td>
            </tr>
            <tr>
                <td>Clonazepam</td>
                <td>Benzodiazepine</td>
                <td>
                    <span class="badge badge-potent">POTENT</span>
                    <span class="potency-text">Long‑acting</span>
                </td>
                <td>Government hospitals</td>
                <td>Long half‑life; not primarily a hypnotic.</td>
            </tr>
            <tr>
                <td>Diazepam</td>
                <td>Benzodiazepine</td>
                <td>
                    <span class="badge badge-potent">POTENT</span>
                    <span class="potency-text">Long‑acting</span>
                </td>
                <td>Government hospitals</td>
                <td>Long‑acting; muscle‑relaxant and anxiolytic.</td>
            </tr>
            <tr>
                <td>Bromazepam</td>
                <td>Benzodiazepine</td>
                <td>
                    <span class="badge badge-light">LIGHT</span>
                    <span class="potency-text">Mild sedative</span>
                </td>
                <td>Government sector</td>
                <td>Less potent hypnotic; more anxiolytic profile.</td>
            </tr>
            <tr>
                <td>Midazolam (injection)</td>
                <td>Benzodiazepine (anesthetic)</td>
                <td>
                    <span class="badge badge-extreme">EXTREMELY POTENT</span>
                    <span class="potency-text">Anesthetic‑level</span>
                </td>
                <td>Government hospitals (injection only)</td>
                <td>Used for anesthesia and procedures; not a routine insomnia treatment.</td>
            </tr>
        </table>

        <h3>Orexin Receptor Antagonist</h3>
        <table>
            <tr>
                <th>Drug</th>
                <th>Class</th>
                <th>Potency</th>
                <th>Availability (UAE)</th>
                <th>Notes</th>
            </tr>
            <tr>
                <td>Lemborexant 5–10 mg</td>
                <td>Dual orexin receptor antagonist (DORA)</td>
                <td>
                    <span class="badge badge-extreme">EXTREMELY POTENT</span>
                    <span class="potency-text">Strong maintenance effect</span>
                </td>
                <td>Private pharmacies</td>
                <td>Novel mechanism; reduces wake drive rather than amplifying GABA.</td>
            </tr>
        </table>

        <h3>Sedating Antidepressants</h3>
        <table>
            <tr>
                <th>Drug</th>
                <th>Class</th>
                <th>Potency</th>
                <th>Availability (UAE)</th>
                <th>Notes</th>
            </tr>
            <tr>
                <td>Amitriptyline</td>
                <td>Tricyclic antidepressant</td>
                <td>
                    <span class="badge badge-moderate">MODERATE</span>
                    <span class="potency-text">Sedating</span>
                </td>
                <td>Government (SCD)</td>
                <td>Off‑label for insomnia; strong H<sub>1</sub> and anticholinergic effects.</td>
            </tr>
            <tr>
                <td>Amitriptyline + Chlordiazepoxide</td>
                <td>TCA + benzodiazepine combination</td>
                <td>
                    <span class="badge badge-moderate">MODERATE</span>
                    <span class="potency-text">Mixed sedative</span>
                </td>
                <td>Government (SCD)</td>
                <td>Used where both mood and anxiety symptoms are present.</td>
            </tr>
            <tr>
                <td>Trazodone</td>
                <td>Serotonin antagonist and reuptake inhibitor</td>
                <td>
                    <span class="badge badge-moderate">MODERATE</span>
                    <span class="potency-text">Low‑dose hypnotic</span>
                </td>
                <td>Government + private (SCD)</td>
                <td>Common off‑label hypnotic at low doses.</td>
            </tr>
            <tr>
                <td>Mirtazapine</td>
                <td>NaSSA antidepressant</td>
                <td>
                    <span class="badge badge-moderate">MODERATE</span>
                    <span class="potency-text">Sedating at low dose</span>
                </td>
                <td>Government (SCD)</td>
                <td>Strong H<sub>1</sub> blockade; often used when depression and insomnia coexist.</td>
            </tr>
        </table>

        <h3>Off‑Label Adjunctive Agents</h3>
        <table>
            <tr>
                <th>Drug</th>
                <th>Class</th>
                <th>Potency</th>
                <th>Availability (UAE)</th>
                <th>Notes</th>
            </tr>
            <tr>
                <td>Gabapentin</td>
                <td>Gabapentinoid</td>
                <td>
                    <span class="badge badge-moderate">MODERATE</span>
                    <span class="potency-text">Adjunctive</span>
                </td>
                <td>Government + private</td>
                <td>Off‑label; may improve sleep in patients with pain or anxiety.</td>
            </tr>
            <tr>
                <td>Pregabalin</td>
                <td>Gabapentinoid</td>
                <td>
                    <span class="badge badge-moderate">MODERATE</span>
                    <span class="potency-text">Adjunctive</span>
                </td>
                <td>Government + private</td>
                <td>Off‑label; similar rationale to gabapentin.</td>
            </tr>
            <tr>
                <td>Phenobarbital</td>
                <td>Barbiturate</td>
                <td>
                    <span class="badge badge-extreme">EXTREMELY POTENT</span>
                    <span class="potency-text">Strong CNS depressant</span>
                </td>
                <td>Government (rare use)</td>
                <td>Rarely used due to safety and dependence concerns.</td>
            </tr>
        </table>

        <h3>Antihistamines and OTC Products</h3>
        <table>
            <tr>
                <th>Drug</th>
                <th>Class</th>
                <th>Potency</th>
                <th>Availability (UAE)</th>
                <th>Notes</th>
            </tr>
            <tr>
                <td>Doxylamine</td>
                <td>First‑generation antihistamine</td>
                <td>
                    <span class="badge badge-light">LIGHT</span>
                    <span class="potency-text">Mild–moderate</span>
                </td>
                <td>Rx</td>
                <td>H<sub>1</sub> antagonist; sedating, with anticholinergic effects.</td>
            </tr>
            <tr>
                <td>Diphenhydramine</td>
                <td>First‑generation antihistamine</td>
                <td>
                    <span class="badge badge-light">LIGHT</span>
                    <span class="potency-text">Mild–moderate</span>
                </td>
                <td>Rx + OTC</td>
                <td>Component of Panadol Night; sedating with anticholinergic burden.</td>
            </tr>
            <tr>
                <td>Panadol Night</td>
                <td>Paracetamol + diphenhydramine</td>
                <td>
                    <span class="badge badge-light">LIGHT</span>
                    <span class="potency-text">OTC sedative</span>
                </td>
                <td>OTC (community pharmacies)</td>
                <td>Analgesic plus sedating antihistamine; widely accessible.</td>
            </tr>
            <tr>
                <td>Promethazine</td>
                <td>First‑generation antihistamine</td>
                <td>
                    <span class="badge badge-light">LIGHT</span>
                    <span class="potency-text">Sedating</span>
                </td>
                <td>Rx only</td>
                <td>Strong antihistamine; sometimes used for short‑term sedation.</td>
            </tr>
        </table>

        <p style="font-size:13px; color:#9cffc9; margin-top:10px;">
            <strong>Note:</strong> Ramelteon and several classic hypnotic benzodiazepines (temazepam, estazolam,
            flurazepam) are reported as not available in the UAE at the time of this review.
        </p>
    </div>

    <!-- Novel Treatments -->
    <div class="box" id="novel">
        <h2>Novel & Emerging Treatments</h2>
        <p>
            Dual orexin receptor antagonists such as lemborexant represent a mechanistically distinct approach to
            insomnia treatment, targeting wake drive rather than amplifying GABAergic inhibition. As more DORAs and
            melatonin‑receptor agonists become available globally, their potential integration into UAE practice will
            depend on regulatory approval, cost, and clinician familiarity. Digital therapeutics and structured CBT‑I
            programs are also expanding internationally and may complement pharmacological strategies in the region.
        </p>
    </div>

    <!-- Conclusion -->
    <div class="box" id="conclusion">
        <h2>Conclusion</h2>
        <p>
            Insomnia pharmacotherapy in the United Arab Emirates spans Z‑drugs, benzodiazepines, sedating
            antidepressants, antihistamines, gabapentinoids, and a growing presence of orexin receptor antagonists.
            Understanding receptor‑level mechanisms, relative sedative potency, and local availability can help
            clinicians position these agents more rationally within individualized treatment plans. This review is
            intended as an educational resource and does not replace clinical guidelines, regulatory documents, or
            patient‑specific medical judgment.
        </p>
    </div>

    <!-- References -->
    <div class="box" id="references">
        <h2>References</h2>
        <p style="font-size:14px;">
            This educational review is based on established pharmacology of hypnotic agents, publicly available
            information on drug mechanisms, and local availability data as reported at the time of writing. Clinicians
            should consult up‑to‑date formularies, regulatory circulars, and evidence‑based guidelines when making
            prescribing decisions.
        </p>
    </div>

    <footer style="text-align:center; margin:30px 0; font-size:13px; color:#8fcf8f;">
        © 2026 Khalid — Neuropsychopharmacology Research &amp; Analysis
    </footer>

</div>

</body>
</html>
<script>
document.querySelectorAll("nav a").forEach(link => {
    link.addEventListener("click", function(e) {
        e.preventDefault();

        const targetURL = this.href;
        const overlay = document.getElementById("loading-overlay");
        const text = document.getElementById("loading-text");

        overlay.style.display = "flex";
        let percent = 0;

        const interval = setInterval(() => {
            percent += 2;
            text.textContent = percent + "%";

            if (percent >= 100) {
                clearInterval(interval);
                window.location.href = targetURL;
            }
        }, 30);
    });
});
</script>
<script src="global.js"></script>
